Keifei Pharma | Semaglutide 16.25mg (Semaglufei) | Compound Peptide Pen
Advanced GLP-1 Receptor Research Compound
Keifei Pharma Semaglufei 16.25mg is an investigational GLP-1 receptor peptide research compound studied in laboratory environments for its role in metabolic signalling pathways, glucose regulation mechanisms, and appetite-related endocrine responses.
Semaglutide-related compounds are widely referenced in scientific research exploring incretin hormone activity, insulin secretion dynamics, and energy balance regulation within controlled experimental and biochemical models.
Developed as a 16.25mg compound peptide pen, this formulation is designed for laboratory preparation and controlled research applications where GLP-1 receptor activity and metabolic pathway investigation are of scientific interest.
Keifei Pharma Semaglufei 16.25mg Compound Peptide Pen
• GLP-1 receptor research compound studied in metabolic signalling models
• Investigated in glucose regulation and insulin response research
• Of interest in appetite signalling and energy balance studies
• Explored in incretin hormone pathway research environments
• 16.25mg pen format designed for laboratory preparation use
• High-purity investigational formulation from Keifei Pharma
• Manufactured for stability, consistency, and research reliability
• Strictly intended for laboratory research use only
⚖️ DISCLAIMER
This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPHRA) for human or animal use.
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.
Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
